Key facts
- Interdict Bio’s last known valuation is $35.0M (Sep 2025).
- It has raised $26.5M; the latest was Early Stage VC ($17.5M) in Sep 2025.
- Notable investors include Venrock, Altitude Life Science Ventures, Mission Bay Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Interdict Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Interdict Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Interdict Bio
Developer of a small-molecule therapeutics platform designed to address historically undruggable targets. The company's platform specializes in addressing strongly validated yet historically undruggable targets in oncology, rare diseases, neurodegeneration, and autoimmunity, enabling healthcare professionals to treat their patients effectively.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2022
- Employees
- 14
- Website
- interdictbio.com/
- Ownership
- Privately Held (backing)
Interdict Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Interdict Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Interdict Bio in its N-PORT filings yet. We sweep new filings monthly.